Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
about
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.CD4 T-cell immunotherapy for chronic viral infections and cancerStructural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cellsStructure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicityLoss of CD4 T-cell-dependent tolerance to proteins with modified amino acidsSystems Proteomics View of the Endogenous Human Claudin Protein FamilyThe antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responsesThe cellular redox environment alters antigen presentationThe melting pot of the MHC II peptidomeThe MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation.Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies.Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingInterleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.Peptide identification by tandem mass spectrometry with alternate fragmentation modes.Cardiac mitochondrial matrix and respiratory complex protein phosphorylationMajor histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High SpecificityThe spectral networks paradigm in high throughput mass spectrometry.Testing the theory of immune selection in cancers that break the rules of transplantation.Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Human Tumor Antigens Yesterday, Today, and Tomorrow.Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populationsAutoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Human c-SRC kinase (CSK) overexpression makes T cells dummy.Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.Current Strategies to Enhance Anti-Tumour Immunity.
P2860
Q26796314-7F670351-273E-4096-A08D-8C674EC09E80Q27022957-507F9964-0945-43E3-8E39-D493F116B91CQ27660843-AD4A04FE-BFFC-4AB6-9AEA-82BFEC9389F2Q27680213-D20D8C60-7914-4394-A448-49058033AF40Q28243525-D82CB928-C090-4BAE-943F-A9D1FFEE0626Q28271194-17C1FF83-4283-4B33-B875-1CFFF5AD6D24Q30252521-ED219057-04F8-4879-8CB2-4379F29FAE81Q30303138-7400488F-D1F7-4E5F-B923-A9616CA7FE17Q30412320-6F157CC1-4FE8-496C-9200-C49E057923D6Q30425111-A1294D05-7B7A-41CB-BC7E-8BE71F2414AEQ33551458-BBD3D91C-065A-45B3-94CE-D66C2ACBE840Q33930126-75387FDF-A1A4-40E0-8D4B-5D719A3FC59EQ34283588-ECA29271-95A8-40F8-B2FB-1F9071D5D955Q34676583-C2C823BA-80C0-4D12-AE45-228F3DCDD6A0Q35458694-6521AB96-6AEC-498F-A39B-CD4FBB92ED18Q35815990-A432D283-4EE3-4616-A3A2-5F6DAA0049F8Q35816845-3CCB570A-1D8C-4EE3-9131-98F16C54639CQ35978264-41D90B85-F22B-48EB-9236-549C047CB38EQ36211835-DF2448E2-4B85-463F-854B-5FD3F1849E07Q36312517-08D22954-7886-4797-B162-9FED97B0FAEBQ36386903-3C6A2B25-3C34-40A7-850E-3679C86EB30AQ36778316-82A71FB1-5600-48F5-B16A-5C392A30D7A5Q37483521-EA2327D1-94FA-4E08-8096-158622E56505Q37662210-E7EBCED2-0BCE-441C-9723-BC2EA1D6F626Q37952805-6DF73735-A3F8-46A3-8AD8-9445D9A7E6FDQ38227889-38C602F9-D10F-4882-AB17-AFDC23B7AD15Q39279256-0AF3877A-65DA-4D36-9003-DF535974C16FQ39506462-9F5A5223-AF03-4058-AFA1-22230C9E15FBQ41449614-C46919F0-4DDE-4F6C-A21F-45BB1066EFEDQ47190955-FDB5D951-16D5-4B72-9374-5FCBE0BC14A5Q48105379-65A9E5EC-41B2-4D82-820A-4444034DE70DQ51556710-2E37CF1B-7013-4843-8250-8F09F8B1D1F9Q51746346-D1D644BD-2D3F-4058-9919-5878FE454F46Q52344613-06403D0A-EA4A-474B-AD4D-2A0A38831F85
P2860
Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Identification of tumor-associ ...... s as targets for immunotherapy
@ast
Identification of tumor-associ ...... s as targets for immunotherapy
@en
type
label
Identification of tumor-associ ...... s as targets for immunotherapy
@ast
Identification of tumor-associ ...... s as targets for immunotherapy
@en
prefLabel
Identification of tumor-associ ...... s as targets for immunotherapy
@ast
Identification of tumor-associ ...... s as targets for immunotherapy
@en
P2093
P2860
P356
P1476
Identification of tumor-associ ...... s as targets for immunotherapy
@en
P2093
A Michelle English
Andrew Norris
Angela L Zarling
Donald F Hunt
Florence R Depontieu
Suzanne L Topalian
Theresa M Salay
Tracee L McMiller
Victor H Engelhard
P2860
P304
12073-12078
P356
10.1073/PNAS.0903852106
P407
P577
2009-07-06T00:00:00Z